$1.570
-0.153 (-9.77%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
Acrivon Therapeutics, Inc. (ACRV) Moving Averages Convergence Divergence (MACD) indicator is -0.07, suggesting ACRV is Strong sell.
Acrivon Therapeutics, Inc. (ACRV) 20-Day simple moving average is 1.72, while Acrivon Therapeutics, Inc. (ACRV) share price is $—, making it Sell.
Acrivon Therapeutics, Inc. (ACRV) 60-Day simple moving average is 1.93, while Acrivon Therapeutics, Inc. (ACRV) share price is $—, making it Sell.
Technical Analysis for ACRV
AI Technical ACRVAs of 2026-11-03, the technical board for Acrivon Therapeutics, Inc. (ACRV) reads strong sell: 1 indicators are flashing buy, 9 are indicating sell, and 3 are neutral. Price at $1.57 sits below every tracked moving average (5-day, 10-day, 20-day, 60-day and 200-day).
Momentum readings: RSI stands at 37.468, MACD stands at -0.0742 (Sell), Stochastic %K stands at 28.885, Stochastic %D stands at 31.06 and CCI stands at -187.044 (Buy).
ACRV trades below the 60-day SMA (1.93) and below the 200-day SMA (1.76). Immediate resistance sits at Classic R1 1.86, then R2 2.03. Support sits at Classic S1 1.51, then S2 1.33.
Acrivon Therapeutics, Inc. (ACRV) Support & Resistance Level
Acrivon Therapeutics, Inc. (ACRV) Technical Indicators
2026-11-03
| Name | Value |
|---|---|
| RSI_14 | 37.468 |
| STOCHk_14_3_3 | 28.885 |
| STOCHd_14_3_3 | 31.060 |
| CCI_20 | -187.044 |
| AO_5_34 | -0.216 |
| MOM_10 | -0.165 |
| MACD_12_26_9 | -0.074 |
Acrivon Therapeutics, Inc. (ACRV) Relative Strength Index (RSI_14) is 37.468, creating a Neutral signal.
Acrivon Therapeutics, Inc. (ACRV) Stochastic %K is 28.885, creating a Neutral signal.
Acrivon Therapeutics, Inc. (ACRV) Stochastic %D is 31.060, creating a Neutral signal.
Acrivon Therapeutics, Inc. (ACRV) CCI_20 is -187.044, creating a Buy signal.
Acrivon Therapeutics, Inc. (ACRV) Awesome Oscillator (AO) is -0.216, creating a Sell signal.
Acrivon Therapeutics, Inc. (ACRV) Momentum (MOM) is -0.165, creating a Sell signal.
Acrivon Therapeutics, Inc. (ACRV) Moving Average Convergence Divergence (MACD) is -0.074, creating a Sell signal.
Acrivon Therapeutics, Inc. (ACRV) Moving Average
2026-11-03
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 1.631 | Sell |
| MA_10 | 1.683 | Sell |
| MA_20 | 1.720 | Sell |
| MA_60 | 1.929 | Sell |
| MA_200 | 1.759 | Sell |
| MA_250 | 1.864 | Sell |
Acrivon Therapeutics, Inc. (ACRV) 5-Day simple moving average is 1.631, while Acrivon Therapeutics, Inc. (ACRV) share price is $, making it a Sell.
Acrivon Therapeutics, Inc. (ACRV) 10-Day simple moving average is 1.683, while Acrivon Therapeutics, Inc. (ACRV) share price is $, making it a Sell.
Acrivon Therapeutics, Inc. (ACRV) 20-Day simple moving average is 1.720, while Acrivon Therapeutics, Inc. (ACRV) share price is $, making it a Sell.
Acrivon Therapeutics, Inc. (ACRV) 60-Day simple moving average is 1.929, while Acrivon Therapeutics, Inc. (ACRV) share price is $, making it a Sell.
Acrivon Therapeutics, Inc. (ACRV) 200-Day simple moving average is 1.759, while Acrivon Therapeutics, Inc. (ACRV) share price is $, making it a Sell.
Acrivon Therapeutics, Inc. (ACRV) 250-Day simple moving average is 1.864, while Acrivon Therapeutics, Inc. (ACRV) share price is $, making it a Sell.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.